NEC、「令和3年度 再生可能エネルギーアグリゲーション実証事業」に参画

TOKYO, Oct 1, 2021 - (JCN Newswire) - NECは、経済産業省が公募する実証事業「令和3年度 再生可能エネルギーアグリゲーション実証事業」(注1)に、東芝ネクストクラフトベルケ株式会社をリーダーとしたコンソーシアム(注2)内の再エネアグリゲーター(注3)として参画します。

本事業の中でNECは、容量1.7MWhの大型蓄電システムを2021年12月にNEC我孫子事業場へ設置し、再エネアグリゲーターの事業にとって重要となるインバランス(注4)回避と収益性向上に関する検証を行います。今回、東急不動産株式会社の協力のもと、自社事業場外にある発電設備と連携してならし効果(注5)によるインバランス回避の実証を行う予定です。

本事業は、変動性の高い太陽光発電、風力発電等の再生可能エネルギー発電設備と蓄電池等の分散型エネルギーリソース(Distributed Energy Resource、以下DER)を組み合わせ、需給バランス確保のための発電量予測や、リソース制御に必要となる技術等の実証を行うことで、DERを活用した安定かつ効率的な電力システムの構築と、再生可能エネルギーの普及拡大を図ることを目的として行われるものです。

現在日本では、FIT(注6)制度のもと再生可能エネルギーの導入が進んでいます。2021年4月からは電力の需給調整市場が段階的に立ち上がっており、再生可能エネルギーや蓄電池などのDERの活用が期待されています。2022年4月からは、再生可能エネルギーの主力電源化を見据えて、FIP(注7)制度への移行が予定されています。FIP制度下で発電事業者は、正確な発電量予測に基づく計画値同時同量(注8)の責務が課されるほか、変動する市場価格に応じた最適な取引によるマーケットリスクへの対応が必要となることから、再生可能エネルギーの更なる普及には、これらの課題解決を支援する再エネアグリゲーターの存在が必要となります。

NECは、経済産業省の助成事業「VPP構築実証事業」に初年度の2016年から参加(注9)するなどノウハウを蓄積してきており、今回再エネアグリゲーターとして初めて実証に参画します。本事業では、自社事業場内に設置した大型蓄電システムと太陽光発電設備を活用し、発電量予測技術、蓄電池制御技術、市場取引戦略技術、発電バランシンググループ(以下、BG)と需要BGとの連携によるインバランス回避手法、再エネアグリゲーターの事業性などを検証します。

なお需要BGとの連携については、VPP実証で培った技術を基盤に開発した「NEC Energy Resource Aggregation クラウドサービス」でシステム連携し、検証を行う予定です。

NECは、本事業への参画を通じ、再生可能エネルギーとDERを活用した安定かつ効率的な電力システムの実現と、再エネアグリゲーター事業のさらなる発展に貢献します。

本リリースの詳細は下記をご参照ください。
https://jpn.nec.com/press/202110/20211001_02.html

概要:日本電気株式会社(NEC)

詳細は www.nec.co.jp をご覧ください。


Copyright 2021 JCN Newswire. All rights reserved. www.jcnnewswire.com Via JCN Newswire https://ift.tt/3tXPATt

大阪大学と富士通、誤り耐性量子コンピュータの研究開発体制を強化

TOKYO, Oct 1, 2021 - (JCN Newswire) - 国立大学法人大阪大学(注1)(以下、大阪大学)と富士通株式会社(注2)(以下、富士通)は、量子情報および量子生命研究を推進する大阪大学の「量子情報・量子生命研究センター(Center for Quantum Information and Quantum Biology、以下、QIQB)」内に、両者の共同研究部門として「富士通量子コンピューティング共同研究部門」を10月1日に設置しました。

新設する共同研究部門では、大阪大学の「QIQB」が取り組む量子誤り訂正や量子ソフトウェアの先端技術の研究開発の知見と、富士通が保有するコンピューティング技術や顧客視点に基づく量子技術の応用知見とを融合し、量子ビットに発生する誤りを訂正しながら正確に計算を実行できる誤り耐性量子コンピュータの実現に向けた基盤技術を研究開発します。具体的には、数千量子ビット規模で動作する誤り耐性量子計算のための量子ソフトウェアを研究開発し、その動作検証技術を開発します。

両者は、今後も本共同研究部門を通した強固な連携により、誤り耐性量子コンピュータの実現に向けた研究開発を効率良く推進し、求解が困難な社会課題の解決に貢献していきます。

背景

量子コンピュータは、量子力学特有の量子重ね合わせ状態と量子エンタングルメント(注3)の特性を生かし、現在のコンピュータを圧倒的に凌駕する計算速度の実現が期待されています。特に、複雑かつ大規模な実問題を高速に解くことが求められる創薬や金融分野などでの将来的な活用において、量子誤り訂正符号により冗長性を持たせることで、量子的な誤りを訂正しながら正確に計算を実行可能な誤り耐性量子コンピュータの実現が鍵となります。

大阪大学は、2020年3月に量子情報と量子生命研究を推進する「QIQB」を設立し、量子コンピューティング、量子情報融合、量子情報デバイス、量子通信・セキュリティ、量子計測・センシング、量子生命科学などの幅広い分野で研究に取り組んでおり、これらの分野間および他の学問分野との学際融合研究を推進しています。また、国立研究開発法人科学技術振興機構(JST)の「共創の場形成支援プログラム(COI-NEXT)」(注4)における量子技術分野で、「QIQB」が量子ソフトウェア研究拠点として採択され、日本の量子技術イノベーション戦略の一翼を担っています。

富士通は、コンピューティング技術のさらなる性能向上を目指し、2020年より、国内外の研究機関と連携し、量子コンピューティングの研究開発を本格的に進めています。また、量子インスパイアード技術(注5)を応用して組合せ最適化問題を高速に解く富士通の「デジタルアニーラ」を、創薬、物流などの顧客に提供し、実現場における複雑な問題の解決を支援しています。

両者は、2020年10月に量子誤り訂正に関する共同研究(注6)を開始しており、今回、「富士通量子コンピューティング共同研究部門」を新設することで、誤り耐性量子コンピュータの実現に向けた研究開発体制をさらに強化します。

「富士通量子コンピューティング共同研究部門」について

1. 名称: 富士通量子コンピューティング共同研究部門 (Fujitsu Quantum Computing Joint Research Division)

2. 所在地: 大阪大学 世界最先端研究機構「量子情報・量子生命研究センター(QIQB)」内 (大阪府豊中市)

3. 設置期間: 2021年10月1日から2024年3月31日まで

4. 研究内容: 誤り耐性量子コンピュータのための量子ソフトウェアの研究開発
- 数千量子ビット規模の量子コンピュータを想定し、誤りが入った複数の量子ビットから元の情報を復元して量子誤り訂正を行うアルゴリズムの構築と、そのアルゴリズムを性能評価する技術の研究開発を行います。
- 量子誤り訂正符号によって実現される論理量子ビット(注7)を用いた量子計算を行うために、プログラムの入力から結果の出力にわたり必要となる一連のソフトウェアの研究開発と実装に取り組みます。また、将来の実機を想定したノイズを含む仮想マシン環境を用いて、これらのソフトウェアの動作検証を行います。

5. 両者の役割:
<大阪大学>
- 大阪大学が保有する量子誤り訂正技術の知見を活用して、数千量子ビット規模の量子コンピュータにおける量子誤り訂正の性能評価技術の研究開発を行う。
- 論理量子ビットを用いた量子計算を行うために必要な一連のソフトウェアの研究開発および仮想マシンでの動作検証を行う。
<富士通>
- 富士通が保有するコンピューティング技術の知見を活用し、数千量子ビット規模の量子コンピュータにおける量子誤り訂正を行うアルゴリズムの構築を行う。
- 論理量子ビットを用いた量子計算を行うために必要な一連のソフトウェアの研究開発、仮想マシンへの実装および動作検証支援を行う。

今後について

両者は、量子コンピュータを活用した科学技術の発展に向けて、様々な研究機関や企業との共創の場を形成し、本共同研究によって得られた成果を共有して、持続可能な社会を実現するイノベーションの創出に生かすことで、量子コンピュータの早期実用化を目指します。また、それを見据えた量子技術分野の人材育成に、産学一体となって取り組んでいきます。

本リリースの詳細は下記をご参照ください。
https://pr.fujitsu.com/jp/news/2021/10/1.html

概要: 富士通株式会社

詳細は http://jp.fujitsu.com/ をご覧ください。


Copyright 2021 JCN Newswire. All rights reserved. www.jcnnewswire.com Via JCN Newswire https://ift.tt/3tXPATt

Edison Oncology and Apollomics Announce Treatment of First Patient with EO1001 (APL-122) in a Phase I/IIa Clinical Trial

MENLO PARK, CA and HELSINKI, FINLAND, Oct 1, 2021 - (ACN Newswire) - Edison Oncology Holding Corp. ("Edison Oncology"), a company established to develop new therapies targeting the fight against cancer, and Apollomics Inc. ("Apollomics"), an innovative biopharmaceutical company committed to the discovery and development of mono- and combination oncology therapies, reported that the first patient was dosed with EO1001 (APL-122) in a Phase I/IIa clinical trial in patients with advanced solid tumors. EO1001 is a potent irreversible tyrosine kinase inhibitor (TKI) that has demonstrated inhibition of EGFR (ErbB1), HER2 (ErbB2) and HER4 (ErbB4) as a single agent in laboratory studies.

"We are thrilled to see our first patient treated with EO1001 and hope that the potential safety and efficacy suggested by our preclinical data has the potential to translate into clinical benefits for patients suffering from cancer," said Jeffrey Bacha, B.Sc., MBA, Co-Founder and Chief Executive Officer of Edison Oncology. "Our preclinical studies have shown that EO1001 is potent against multiple activating mutations in the intracellular domain of EGFR. We look forward to the results from this first clinical trial as we believe EO1001 has the potential to address unmet medical needs in many types of cancer including non-small cell lung cancer, breast cancer and glioblastoma."

The Phase I/IIa clinical trial will enroll up to 50 patients and is being conducted in Australia under contract service provided by Senz Oncology Pty Ltd. The objective of this first-in-human clinical trial is to examine the safety and tolerability of EO1001 in patients with metastatic or advanced stage ErbB-1(EGFR), ErbB-2(HER2) and/or ERbB-4 (HER4) positive cancer. Patients with relapsed ErbB-positive cancers in solid tumors, including patients with central nervous system (CNS) involvement, will be enrolled at several clinical sites in Australia.

Sanjeev Redkar, PhD, Co-Founder and President of Apollomics, added, "We are pleased to achieve this important milestone in the development of EO1001 which we refer to as APL-122. In preclinical models, APL-122 demonstrated activity in ErbB positive tumors and the ability to penetrate and treat cancers in the CNS. Therefore, this Phase I/IIa study is inclusive of patients with brain metastases. Advancing into human clinical trials marks a pivotal step in our development of this promising cancer therapy."

Dr. Sophia Frentzas, medical oncologist and clinical researcher at Monash Cancer Center in Melbourne, Australia and Principal Investigator for the clinical trial said, "ErbB positive tumors represent a significant patient population with unmet clinical needs. These include patients with HER2 (ErbB2) positive breast cancer and EGFR (ErbB1) mutant lung cancer who have acquired resistance, or are refractory, to frontline targeted therapy. They also include those patients with other tumour types where the ErbB pathway has been increasingly shown to be a clinically significant oncogenic driver (e.g. GBM, endometrial, ovarian, bladder cancer and others). Cross-talk between ErbB family members is implicated in resistance to treatment and the growing incidence of central nervous system metastases plays a significant role in patient morbidity and mortality. In particular, the latter presents a significant limitation with currently available targeted therapies. EO1001 is an oral, brain-penetrating, uniquely potent, pan-ErbB inhibitor. We look forward to exploring its safety and efficacy in this first-in-human trial."

On February 9, 2021, Edison Oncology and Apollomics announced an exclusive licensing agreement whereby Apollomics will develop and commercialize EO1001 (APL-122) globally, except in Mainland China, Hong Kong and Taiwan.

About EO1001

EO1001 is an irreversible tyrosine kinase inhibitor (TKI) that has demonstrated inhibition of EGFR (ErbB1), HER2 (ErbB2) and HER4 (ErbB4) as a single agent in laboratory studies. EO1001 is potent against mutations in the intracellular domain of EGFR that are typically found in diseases such as Non-Small Cell Lung Cancer (NSCLC) including T790M, L858R and d746-750, HER2 (ErbB2) which is prominent in breast cancer, and against the EGFR-variant III (EGFRvIII) that is characteristic of glioblastoma. In preclinical trials, EO1001 has been well-tolerated and demonstrated the ability to enter the central nervous system (CNS) following oral dosing and activity against treatment-resistant EGFRvIII-driven tumors, including malignancies in CNS, in vivo. EO1001 is referred to as APL-122 by Apollomics.

About Edison Oncology

Edison Oncology was founded in 2018 by experienced life science industry veterans to develop and commercialize new therapies targeting the fight against cancer. Edison Oncology leverages a deep understanding of cancer biology and cancer pharmacology in order to identify and advance underdeveloped drug candidates with the potential to overcome treatment resistance and improve survival outcomes and quality of life for cancer patients.

About Apollomics Inc.

Apollomics Inc. is an innovative biopharmaceutical company committed to the discovery and development of monotherapies and combination therapies of tumor-targeting and immuno-oncology agents. The Company's product pipeline has several programs at different stages of development, including novel, humanized monoclonal antibodies that restore the body's immune system to recognize and kill cancer cells, and targeted therapies against uncontrolled growth signaling pathways. Apollomics has operating entities in Foster City, California, USA, Hangzhou and Shanghai, China. For more information, please visit www.apollomicsinc.com.

Edison Oncology Contacts:

Company Contact:
Jeffrey Bacha
Chief Executive Officer
(650) 690-1927
jb@eohc.com

Media and Investor Relations Contact:
Amato & Partners, LLC
Investor Relations Counsel
admin@amatoandpartners.com

Apollomics Contacts:

Investor Contact:
Wilson W. Cheung
Chief Financial Officer
(650) 209-4436
wcheung@apollomicsinc.com

U.S. Media Contact:
Remy Bernarda
Corporate Communications
(415) 203-6386
remy.bernarda@apollomicsinc.com

China Media Contact:
Porda Havas International Finance Communications Group
Kelly Fung
General Manager
(852) 3150 6763
kelly.fung@pordahavas.com

Phoenix Fung
Vice President
(852) 3150 6773
phoenix.fung@pordahavas.com

Copyright 2021 ACN Newswire. All rights reserved. www.acnnewswire.com

source https://www.acnnewswire.com/press-release/english/69965/

モンスーン・ブロックチェーンによるビットコインラチナムを用いた次世代暗号通貨環境の強化

カリフォルニア州パロアルト、2021年10月1日 - (JCN Newswire) - カリフォルニア州パロアルトに拠点を置く革新的なブロックチェーン企業、モンスーン・ブロックチェーンは、ビットコインラチナムを動かすための次世代デジタル暗号通貨エコシステムを公表した。ビットコインラチナムは保険付きで資産担保型の暗号通貨だ。ビットコインラチナムは、ビットコインの環境を基礎に構成されており、エコに、速く、安全に、デジタルでの取引を大きく前進させようとしている。モンスーン・ブロックチェーンは、ビットコインラチナム財団に代わりビットコインラチナムネットワークの主要開発者としての役割を果たしている。

ビットコインラチナムは、オープンな暗号通貨技術として構築され、大規模取引、サイバーセキュリティ、デジタル資産管理に対応している。モンスーン・ブロックチェーンは、ビットコインラチナムの公式な属性、差別化要因、主要な利点を公開しており、それには以下の分野が含まれる。

取引量の増加

ビットコインラチナムは拡張性の高いネットワークを提供する。最大毎秒1万件、1日に数百万件の取引に対応し、小売店での取引を促進する。そのスケーラブルな構造により、需要に応じて取引レートを上げることが可能だ。ビットコインラチナムはPoS(プルーフ・オブ・ステーク)というコンセンサス方式を採用しているため、1分あたりの取引量が増えても取引手数料を低く抑えることができる。

コスト削減

ビットコインラチナムは、従来のビットコイン取引のコストを平均数ドルからわずか数セントにまで削減し、2021年には取引あたりの平均手数料を0.1ドルにしている。これは、エネルギー効率の高いコンセンサスプロトコル、承認されたノード構成、性能の高いノード相互接続、確認時間の短縮など、様々なメカニズムにより実現されている。

スピードの向上

ビットコインラチナムは、効率的なコンセンサスメカニズムを採用することで、ビットコインと比較して圧倒的に優れたオンチェーン決済ネットワークを実現し、平均取引確認時間は3~5秒になっている。これにより、取引規模の縮小と取引量増加が可能になる。

環境に優しく、エネルギー効率の高いコンセンサス

ビットコインラチナムは、PoW(プルーフ・オブ・ワーク)に基づくネットワークが抱える問題に対処するため、PoS(プルーフ・オブ・ステーク)メカニズムの高度バージョンを使用している。PoSにより、LTNM保有者は自らのコインを担保としてビットコインラチナムネットワークに賭けることで報酬を得ることができ、これは電力消費量の削減につながる。ビットコインのような既存のトークンでは取引あたり最大885 kWh以上、イーサリアムでは102kWh以上のエネルギー消費が必要だが、ビットコインラチナムでは取引あたり0.00015 kWhにまで削減される。

保険と資産担保付き

既存の暗号通貨とは異なり、ビットコインラチナムは資産担保型の暗号通貨であり、世界最大の保険付きデジタル資産を目指している。その資産担保型はファンドモデルで保有されているため、時間の経過とともに基礎となる資産価値が上昇する。この資産担保型ファンドの成長を加速させるため、取引手数料の8割を通貨の裏付けとなる資産担保型ファンドに入金している。したがって、ビットコインラチナムが採用が増加するほどに資産ファンドの成長が加速され、自己インフレを起こす通貨となる。

コミュニティ主導

ビットコインラチナムは、民主主義を実現するために代表制政府モデルを採用している。コミュニティメンバーがステーキングモデルを介してプロトコルの管理メカニズムに参加するという仕組みだ。既存のプロトコルの多くが抱える致命的な欠陥に対する51%を占める攻撃からビットコインラチナムを守ることを目的としている。

モンスーン・ブロックチェーンは、最初の採用者としてビットコインラチナムを活用し、強力なブロックチェーン技術とビジネスソリューションを開発するほか、世界中の企業や組織の資産をデジタル化して上場する。最初にサービスを提供する業界は、ゲーム、金融サービス、テレコミュニケーション、メディア・エンターテイメント、クラウド・データストレージ等。2021年にビットコインラチナムを公の取引所で始動する予定で進めている。

モンスーン・ブロックチェーンは、ビットコインラチナムの大量導入を促進する戦略的計画の要として、小売取引にトークンを統合する企業との国際パートナーシップを構築している。ビットコインラチナムとモンスーンのブロックチェーンのエコシステムは、保険、エンターテインメント、ゲーム、データストレージ関連の企業を中心に、大幅な導入が進んでいる。

小売取引で使用する暗号通貨の世界的な採用は、着実に増加している。2021年の4ヶ月間で、世界の暗号通貨ユーザー数は1億人から2億人へと倍増し、大手企業も注目している。大手レストランチェーン、映画館、小売店のショッピングサイトなどが、暗号通貨を支払いのために試験的に利用するようになった。

この2年間で、暗号通貨の購入は大幅に簡易化した。大手オンライン決済サービスでは、何億人ものユーザーが暗号通貨の売買を行えるようになっている。銀行決済では、南アジアを拠点とする大手銀行が中央銀行のコンソーシアムと提携し、デジタル通貨の国境を越えた決済システムの試験を開始したと報道されている。

モンスーン・ブロックチェーンのCEO兼創業者であるドナルド・バジーレ氏は、大手金融機関や世界的なIT企業へのクラウドシステム導入に大きな役割を果たしたことで知られるFusion-IO社の元CEOでもある。

バジーレ氏はさらに、2020年11月に新規株式公開で2億3600万ドルを確保した買収企業であるRoman DBDRの共同CEO兼会長も務める。Roman DBDRは、プレミアム支払カードの先駆けであり、世界最大級の金融機関を顧客に持つCompo Secure社との合併を発表した。両社の合併により、総企業価値は約12億ドルになる。Compo Secure社は、新たな暗号通貨のコールドストレージソリューション「Arculus」を間もなく公開する予定になっており、ユーザーは最先端の金属製支払カードにデジタル資産を安全に保管・管理することができる。

ビットコインラチナムに関するさらに詳細な情報はこちらのリンクから。https://bitcoinlatinum.com/

ビットコインラチナムは、教育および情報提供のみを目的としており、投資アドバイスとしての利用は想定していない。証券関連の提案や勧誘として解釈されるものではなく、また個人的な投資アドバイスとして依拠されるものでもない。ビットコインラチナムは、いかなる投資決定を行う前にも、資格を持つ、または登録済みの専門家に相談することを強くお勧めする。

お問い合わせ
会社名 モンスーン・ブロックチェーン株式会社
連絡先 Wei Ming(広報責任者)
メール wei.ming@monsoonblockchaincorporation.com
ウェブサイト https://monsoonblockchaincorporation.com/
住所 2100 Geng Road, Palo Alto, California 94303, USA
電話 +1 800-528-0985

出典 モンスーン・ブロックチェーン・コーポレーション




Copyright 2021 JCN Newswire. All rights reserved. www.jcnnewswire.com Via JCN Newswire https://ift.tt/3tXPATt

テクニカ・ゼン株式会社がIAPP公式トレーニング・パートナーに日本で初めて認定されました

HYOGO, Japan , Oct 1, 2021 - (JCN Newswire) - テクニカ・ゼン株式会社(本社:兵庫県芦屋市、代表取締役:寺川 貴也、以下 テクニカ・ゼン)は、日本で初めて、世界最大のプライバシー専門家のためのNPOであるIAPP (The International Association of Privacy Professionals)の公式トレーニング・パートナー(Official Training Partner, OTP)となりました。


IAPPが提供するCertified Information Privacy Professional(以下、CIPP)認証、Certified Information Privacy Manager(以下、CIPM)認証はプライバシー業界のグローバル認証として広く認知されており、世界中のプライバシーの専門家がその能力を証明するために取得しています。

IAPPが提供する認証は、プライバシー業界に関心がある方にとっては、世界中でプライバシー専門家として活躍する道を開くものです。組織のプライバシー部門で既に責任ある地位に就いている方にとっては、基本となる知識、概念、フレームワーク、ベスト・プラクティスを体系的に学べるため、より確信をもって仕事に臨めるようになり、組織のデータ侵害リスクやプロアクティブなプライバシー対応を実現することができます。

IAPP認証への需要は高いものの、英語でのトレーニングしか提供されていなかったことが日本における普及を妨げていました。

テクニカ・ゼン株式会社は、日本にプライバシー文化を根付かせることを目的に事業を展開しています。今回の認定は、テクニカ・ゼン株式会社の代表取締役である寺川貴也がIAPPと築いてきた信頼関係を基にして実現しました。今回の公式トレーニング・パートナーへの認定は、1年近い交渉を経て、トレーナーが日本語でトレーニングを実施することを含め、合意に至りました。

2018年に施行された欧州一般データ保護規則(GDPR)以来、日本でもプライバシーや個人情報保護への関心が高まっています。2020年の個人情報保護法改正では、よりプライバシーに配慮した改正が進められました。また、日本政府もプライバシー・ガバナンスの導入を積極的に推進しています。

このような時代環境の中、IAPPのCIPMトレーニングはプライバシー・ガバナンスの基礎を日本企業に提供してくれるものと確信しています。また、IAPPのCIPPトレーニングは、国や地域のプライバシー法およびデータ保護法に対する体系だった理解を提供することで、グローバルにビジネスを展開する企業がより完全な理解をもって世界各国でのプライバシー対応を進められるようになる一助となると確信しています。

IAPP会長兼CEOのJ.トレバー・ヒューズ(J. Trevor Hughes)は、今回の提携に関し、以下のコメントを寄せています。「世界中で訓練を受けたプライバシー専門家に対する需要が高まっています。その需要に応えるためにIAPPはOTPプログラムを用意し、各国でトレーニングと資格を提供しています。テクニカ・ゼンが日本で初めてCIPMとCIPPのトレーニングを提供するようになったことは、法律、テクノロジー、ポリシーなどの分野で一流のトレーニングと資格を提供するプログラムをIAPPが日本で提供できるようになったということを意味し、素晴らしいことだと思っています。」

【IAPP公式トレーニングの内容】
テクニカ・ゼン株式会社では、CIPMトレーニング(2021年11月予定)を皮切りに、CIPP/Eトレーニング、CIPTトレーニングを順次提供する予定です。

[トレーニング・コースに含まれるもの]
- IAPPメンバーシップ(1年分)
- トレーニングのテキスト(eBook)
- 認証試験準備のためのサンプル試験
- 認証試験受験用のバウチャー(認証試験は英語での実施)

【IAPPについて】
IAPPは2000 年に設立された国際プライバシー専門家協会(International Association of Privacy Professionals)です。

データ保護の専門知識として必要な知識体系をグローバルな視点から定義し、専門家に対する知識体系の習得を支援するとともに、継続的に改善することを使命としています。政策に中立な(policy neutral)なNPOで、プライバシー業界に非常に大きな影響力を持っています。本社を米国のニューハンプシャー州ポーツマスに置き、世界100カ国以上に75,000人以上の個人会員を擁しています。

IAPP は、プライバシー保護とデータ保護に関するトレーニング、認証、出版、研究、イベント、ネットワーキングの機会を提供しています。

【テクニカ・ゼン株式会社について】
テクニカ・ゼン株式会社は、グローバル・プライバシー対応を専門とするコンサルティング会社です。2015年の設立以来、大企業からベンチャー企業まで数多くの企業のプライバシー対応を支援してきました。日本だけでなく、グローバルでのプレゼンスが強く、IAPPをはじめ、世界のプライバシー業界のリーダーとネットワークを構築しながらサービスを提供しています。

提供サービス:
IAPP公式トレーニング、コンプライアンス助言サービス、プライバシー対応支援サービス、プライバシー・ソフトウェアの販売、導入支援、会員制サイトでの各国のプライバシー動向情報の提供 等

■会社概要
商号:テクニカ・ゼン株式会社
代表者:代表取締役 寺川 貴也
所在地:〒659-0013 兵庫県芦屋市岩園町23番45号205
設立:2015年11月
事業内容:
- プライバシー、セキュリティ、ガバナンスに関するコンサルティング・サービス
- プライバシー及びセキュリティに関連したソフトウェアの販売代行
URL: https://technica-zen.com/

お問い合わせ先:
テクニカ・ゼン株式会社
IAPP公式トレーニング担当
Tel: 0797 61 7530
info@technica-zen.com


Copyright 2021 JCN Newswire. All rights reserved. www.jcnnewswire.com Via JCN Newswire https://ift.tt/3tXPATt

New treatment for severe corneal inflammation from DED now listed on PBS

MELBOURNE, Oct 1, 2021 - (ACN Newswire) - Today, adults living with severe corneal inflammation from DED (dry eye disease) gain access to a new treatment on the PBS. Ikervis(R), Australia's first PBS listed disease-modifying ciclosporin eye drop treatment for severe keratitis in adults with DED, is now available (1 October 2021).


In-licensed for the first time in Australia by Seqirus, a wholly-owned subsidiary of CSL, from leading ophthalmic company Santen Pharmaceutical Co Ltd, Ikervis contains the disease-modifying treatment ciclosporin, used to reduce inflammation associated with severe keratitis in DED.

According to Professor Stephanie Watson, Ophthalmologist, Clinician Scientist, Ophthalmic Surgeon and Chair of the Ophthalmic Research Institute of Australia, the COVID-19 pandemic is exacerbating DED cases due to increased mask use and screen time.

"We have seen a marked increase in dry eye symptoms among mask users. Typically, DED affects women more than men. According to a US study, women are almost three times more likely to develop DED than men and often progress to more severe forms of the disease earlier than men," said Prof. Watson.

"Keratitis, a condition involving inflammation of the cornea, can be a complication for some patients with DED. Patients with severe keratitis from DED typically present with eye surface damage and inflammation that can sometimes feel like an irritating, itchy or burning sensation with possible blurry vision.

"Patients with severe inflammation of the cornea from DED are often managed with a number of different treatment options, which can be costly for a condition that requires ongoing management. A new subsidised treatment option will improve access for these patients," Prof. Watson said.

"Severe inflammation of the cornea from DED is complicated by a difficult cycle involving inflammation of the eye and damage to the eye surface. Treatment options targeting the immune system are therefore needed to manage these complications from DED, and break the cycle of inflammation," said Dr Margaret Lam, Optometrist, Head of Professional Services at George and Matilda Eyecare and Adjunct Senior Lecturer at the School of Optometry & Vision Science, UNSW.

"Artificial tears aim to provide symptom relief for DED, but don't address the underlying cause of severe corneal inflammation. In these cases, inflammation-reducing treatment options are required. Today's PBS listing of another treatment option for severe keratitis in adults with DED is therefore welcome news for ophthalmologists, optometrists and patients alike," Dr Lam said.

Executive Chair of The B Team Australasia, Lynette has spent the past 16 years living with severe corneal inflammation from DED. Soon after undergoing cataract surgery on both of her eyes in 2005, her eyes became extremely irritated, and she developed double vision. Little did she know at the time, her cataract surgery, coupled with a delayed diagnosis and her advancing age, would result in developing severe corneal inflammation from DED.

"I'm often unable to see things. For instance, I have to carry a magnifying glass when my eyes get blurry, or I develop double vision. Even at the supermarket, I have to carry a magnifying glass to read the food," said Lynette. "When people ask me to look at something for them at work, whether it is a document, or on-screen, depending on the health of my eyes at the time, I find it really difficult."

Lynette maintains it is important for Australian adults living with severe corneal inflammation from DED to have timely access to a range of treatment options. "Had my eye disease been detected earlier, it may not have had such an impact on my life," Lynette said.

Seqirus Head of Medical Affairs for the International Region, Dr Jonathan Anderson, Melbourne, said Seqirus is excited to be introducing the company's second PBS listed treatment option to the eye care market this year.

"Seqirus is committed to broadening access to eye care products to help address unmet clinical needs," said
Dr Anderson. "Today's PBS listing of Ikervis for severe keratitis in adults with DED will give Australians access to another treatment option that has long been available overseas."

About Ikervis
TGA approved in December 2020, Ikervis is a Schedule 4 (S4): Prescription Only Medicine. Ikervis is listed on the PBS from 1 October 2021 for severe keratitis in DED, for prescription by an optometrist or ophthalmologist and requires Authority Approval.

About Seqirus
Seqirus, a CSL company, is a leading provider of essential vaccines and pharmaceuticals. Having served Australia's healthcare needs for over a century, today we operate Australia's only local manufacturing facility for seasonal and pandemic influenza vaccines. Seqirus produces unique medicines in the National Interest, and also in licences a broad range of paediatric and adult vaccines and specialty pharmaceutical products. Visit www.seqirus.com.

Mel Kheradi, VIVA! Communications, m: 0421 551 257, e: melorin@vivacommunications.com.au

References:
1. Ikervis Approved Product Information.
2. The Pharmaceutical Benefits Scheme (PBS). Medicine Status - Ciclosporin. 2021 September 2021]; Available from: https://www.pbs.gov.au/medicinestatus/document/498.html.
3. Krolo, I., et al., Mask-Associated Dry Eye During COVID-19 Pandemic-How Face Masks Contribute to Dry Eye Disease Symptoms. Med Arch, 2021. 75(2): p. 144-148.
4. Barabino, S., A Narrative Review of Current Understanding and Classification of Dry Eye Disease with New Insights on the Impact of Dry Eye during the COVID-19 Pandemic. Ophthalmol Ther, 2021. 10(3): p. 495-507.
5. Amrane, M., et al., Ocular tolerability and efficacy of a cationic emulsion in patients with mild to moderate dry eye disease - a randomised comparative study. J Fr Ophtalmol, 2014. 37(8): p. 589-98.
6. Leonardi, A., B. Flamion, and C. Baudouin, Keratitis in Dry Eye Disease and Topical Ciclosporin A. Ocular Immunology and Inflammation, 2017. 25(4): p. 577-586.
7. Baudouin, C., et al., A randomized study of the efficacy and safety of 0.1% cyclosporine A cationic emulsion in treatment of moderate to severe dry eye. Eur J Ophthalmol, 2017. 27(5): p. 520-530.
8. Stapleton, F., et al., TFOS DEWS II Epidemiology Report. The Ocular Surface, 2017. 15(3): p. 334-365.

Copyright 2021 ACN Newswire. All rights reserved. www.acnnewswire.com

source https://www.acnnewswire.com/press-release/english/69984/

A*STAR and Local SME Work with Vaccination Centres to Deploy AVID System for Filling Syringes

SINGAPORE, Sep 30, 2021 - (JCN Newswire) - The Agency for Science, Technology and Research (A*STAR) has developed an Automated Vaccine Inoculation Dispenser (AVID) system, which replaces the manual step of filling injection syringes with vaccine liquid. AVID is customised for vaccination centres set up by the Ministry of Health and operated by private healthcare providers.

AVID was designed to address the labour-intensive steps of the vaccination process to reduce the workload of healthcare providers, increase accuracy and productivity, and enhance personal safety as well. AVID currently supports the management of vials containing the Pfizer-BioNTech COVID-19 Vaccine, with potential to be customised for the Moderna Vaccine as well.

AVID was developed by researchers from A*STAR's Advanced Remanufacturing and Technology Centre (ARTC) and Singapore Institute of Manufacturing Technology (SIMTech), in collaboration with local systems integrator Sysmatic Global. The innovative HealthTech solution is the first of its kind to automate the extraction of vaccines from vials using a combination of robotic parts, smart sensors and digital technologies.

How it works:

- After thawing of the Pfizer-BioNTech COVID-19 Vaccine, it is diluted in the vial.
- Typically, healthcare providers would then have to extract individual doses of the vaccine (0.3 mL for the Pfizer-BioNTech COVID-19 Vaccine) using syringes. One vial of Pfizer-BioNTech COVID-19 vaccine contains six doses of vaccine after dilution(*).
- AVID automates this step of extraction of the vaccine from the vial into six individual syringes, including the dispersing of bubbles inside the syringes.
- AVID also automatically uncaps and recaps the syringes during the transfer of vaccine from vials to syringes.
- It is easy to use at just the push of some buttons, only needing simple training without any special qualifications required.

Benefits:

- Reduces workload of healthcare providers, by freeing them from the manual step of extracting vaccines from vials to syringes.
- Allows more focused attention by healthcare providers on interacting and communicating with people receiving the vaccinations.
- Increases productivity at vaccination centres via introduction of automated processes that are accurate, consistent, and fast.
- Reduces risks of cross-contamination and vaccine wastage via safe handling by the machine.
- Improves safety for healthcare providers by reducing the handling of sharp syringes during the extraction step.
- The machine's small footprint and low weight (less than 25kg) means it can be easily deployed to any vaccination centre.

Development and Deployment:

- AVID was developed within six weeks from conceptualisation. It is the result of a collaboration between A*STAR's ARTC and SIMTech, which provided expertise in robotics, automation and Industry 4.0 technologies, and Sysmatic Global, which designed, integrated and constructed the machine.
- AVID has been deployed in at least seven vaccination centres so far which administer the Pfizer-BioNTech COVID-19 Vaccine. Thomson Medical, a vaccination centre operator, also supported A*STAR in the development and trial of the machine.

(*) Health Sciences Authority, Singapore: fact sheet for healthcare providers administering Pfizer-BioNTech COVID-19 vaccine: https://bit.ly/3ikKZYt
** AVID fact sheet: www.acnnewswire.com/pdf/files/AVID_ASTAR_Sysmatic_FINAL.pdf

For media queries and clarifications, please contact:
Mr Robin Chan
Head, Corporate Communications
Agency for Science, Technology and Research
Tel: +65 6826 6281
Mobile: +65 9830 2610
Email: robin_chan@hq.a-star.edu.sg

Mr Khoo Kiak Nee
Director, Sysmatic Global
Tel : +65 6246 6859
Mobile : +65 9688 2502
Email : knkhoo@sysmaticgpl.com

About A*STAR
The Agency for Science, Technology and Research (A*STAR) is Singapore's lead public sector R&D agency. Through open innovation, we collaborate with our partners in both the public and private sectors to benefit the economy and society. As a Science and Technology Organisation, A*STAR bridges the gap between academia and industry. Our research creates economic growth and jobs for Singapore, and enhances lives by improving societal outcomes in healthcare, urban living, and sustainability. A*STAR plays a key role in nurturing scientific talent and leaders for the wider research community and industry. A*STAR's R&D activities span biomedical sciences to physical sciences and engineering, with research entities primarily located in Biopolis and Fusionopolis. For ongoing news, visit www.a-star.edu.sg.

Follow us on
- Facebook: https://www.facebook.com/ASTARSG/
- LinkedIn: https://www.linkedin.com/company/astarsg/
- Instagram: https://www.instagram.com/astarsg/
- YouTube: https://www.youtube.com/astartv
- Twitter: https://twitter.com/astarsg

About Sysmatic Global
Sysmatic Global Pte Ltd was established in 2010 as an appointed agent & solution provider for Nitto Seiko, Japan, assembly products. Through the years, we had developed our own design team and evolved to a system integrator providing innovative automation solutions improving customer factory productivity and quality. Coupled with In-house Precision Machining & Sheetmetal fabrication facilities, we strive to provide a full turnkey solution to our customers. Please visit www.sysmaticgpl.com.


Copyright 2021 JCN Newswire. All rights reserved. www.jcnnewswire.com Via JCN Newswire https://ift.tt/3tXPATt

Yeahka Ranks First among Non-bank Independent Institutions in QR Code Payment Acquiring Services

HONG KONG, Sep 30, 2021 - (JCN Newswire) - Yeahka Limited ("Yeahka" or the "Company") (Stock Code: 9923), a leading payment-based technology platform in China, has surpassed others to become one of the most-used aggregate payment service providers by merchants in China.

Yeahka's interim results show, as of the first half of this year, the total number of active merchants using the Company's payment services has reached 6.13 million, up 30.8% year-on-year ("YoY"). Its daily peak count of QR code payment transactions has reached 42 million, compared to 30 million at the end of last year, leading to a rapid increase in its market share in the non-bank independent QR code payment services market. According to Oliver Wyman, Yeahka ranked second with a market share of 14% in China, according to the number of transactions in 2019.

Based on analysis of the latest open data of other key players, Yeahka has surpassed its competitors to become the largest non-bank independent QR code payment services provider by market share in China.

According to iResearch Consulting's 2021 China's Third-Party Payment Industry Report, published this June, the number of merchants covered by integrated payment services has reached 30.48 million, up 19.2% YoY, as of the first half of 2021. Serving 6.13 million merchants, Yeahka has a market share of approximately 20%.

Number of payment transactions through QR code is displayed real-time on Yeahka's official website (www.yeahka.com).

A payment method that integrates multiple relatively fragmented payments through the use of an integrated QR code, aggregate payment brings more convenience to both merchants and consumers. For a services provider, in addition to providing omni-channel payment services, leveraging its technical capabilities to provide value-added services is a crucial next step.

This is also the key to Yeahka's business - the steady and rapid growth of the payment business also propels another important segment for the Company, namely technology-enabled business services. According to Yeahka's interim report, the revenue of this segment increased 86.6% YoY to RMB360 million, and its contribution to the Company's gross profit increased to 43.5% from 34.9% in the same period of 2020, significantly higher than other players in the same field.

Utilized HK$119.8 million in share incentive scheme

Yeahka announced on 23 September that, as of 21 September 2021, the trustee of the Restricted Share Unit ("RSU") Scheme had utilized an aggregate of approximately HK$119.8 million to purchase 4,104,400 Shares from the market at a consideration of HK$26.30 to HK$30.00 per share to hold in trust for the benefit of the RSU participants pursuant to the rules of the RSU Scheme.

According to the announcement, the shares purchased will be rewards for the RSU participants in the RSU Scheme, as an incentive for their contribution to the Company. In addition, the share purchase pursuant to the RSU Scheme also demonstrates the Company's confidence in its business outlook and prospect. The Company will continue to conduct share purchases in the market based on market conditions.



Copyright 2021 JCN Newswire. All rights reserved. www.jcnnewswire.com Via JCN Newswire https://ift.tt/3tXPATt

Yeahka Ranks First among Non-bank Independent Institutions in QR Code Payment Acquiring Services

HONG KONG, Sep 30, 2021 - (ACN Newswire) - Yeahka Limited ("Yeahka" or the "Company") (Stock Code: 9923), a leading payment-based technology platform in China, has surpassed others to become one of the most-used aggregate payment service providers by merchants in China.


Yeahka's interim results show, as of the first half of this year, the total number of active merchants using the Company's payment services has reached 6.13 million, up 30.8% year-on-year ("YoY"). Its daily peak count of QR code payment transactions has reached 42 million, compared to 30 million at the end of last year, leading to a rapid increase in its market share in the non-bank independent QR code payment services market. According to Oliver Wyman, Yeahka ranked second with a market share of 14% in China, according to the number of transactions in 2019.

Based on analysis of the latest open data of other key players, Yeahka has surpassed its competitors to become the largest non-bank independent QR code payment services provider by market share in China.

According to iResearch Consulting's 2021 China's Third-Party Payment Industry Report, published this June, the number of merchants covered by integrated payment services has reached 30.48 million, up 19.2% YoY, as of the first half of 2021. Serving 6.13 million merchants, Yeahka has a market share of approximately 20%.

Number of payment transactions through QR code is displayed real-time on Yeahka's official website (www.yeahka.com).

A payment method that integrates multiple relatively fragmented payments through the use of an integrated QR code, aggregate payment brings more convenience to both merchants and consumers. For a services provider, in addition to providing omni-channel payment services, leveraging its technical capabilities to provide value-added services is a crucial next step.

This is also the key to Yeahka's business - the steady and rapid growth of the payment business also propels another important segment for the Company, namely technology-enabled business services. According to Yeahka's interim report, the revenue of this segment increased 86.6% YoY to RMB360 million, and its contribution to the Company's gross profit increased to 43.5% from 34.9% in the same period of 2020, significantly higher than other players in the same field.

Utilized HK$119.8 million in share incentive scheme

Yeahka announced on 23 September that, as of 21 September 2021, the trustee of the Restricted Share Unit ("RSU") Scheme had utilized an aggregate of approximately HK$119.8 million to purchase 4,104,400 Shares from the market at a consideration of HK$26.30 to HK$30.00 per share to hold in trust for the benefit of the RSU participants pursuant to the rules of the RSU Scheme.

According to the announcement, the shares purchased will be rewards for the RSU participants in the RSU Scheme, as an incentive for their contribution to the Company. In addition, the share purchase pursuant to the RSU Scheme also demonstrates the Company's confidence in its business outlook and prospect. The Company will continue to conduct share purchases in the market based on market conditions.


Copyright 2021 ACN Newswire. All rights reserved. www.acnnewswire.com

source https://www.acnnewswire.com/press-release/english/69972/

A*STAR and Local SME Work with Vaccination Centres to Deploy Automated Systems for Filling Syringes

SINGAPORE, Sep 30, 2021 - (ACN Newswire) - The Agency for Science, Technology and Research (A*STAR) has developed an Automated Vaccine Inoculation Dispenser (AVID) system, which replaces the manual step of filling injection syringes with vaccine liquid. AVID is customised for the vaccination centres which are set up by the Ministry of Health and operated by private healthcare providers.


AVID was designed to address the labour-intensive steps of the vaccination process to reduce the workload of healthcare providers, increase accuracy and productivity, and enhance personal safety as well.

AVID was developed by researchers from A*STAR's Advanced Remanufacturing and Technology Centre (ARTC) and Singapore Institute of Manufacturing Technology (SIMTech), in collaboration with local systems integrator Sysmatic Global. The innovative HealthTech solution is the first of its kind to automate the extraction of vaccines from vials using a combination of robotic parts, smart sensors and digital technologies.

AVID currently supports the management of vials used to contain the Pfizer-BioNTech COVID-19 Vaccine, with potential to be customised for the Moderna Vaccine as well.

How it works:

- After thawing of the Pfizer-BioNTech COVID-19 Vaccine, it is diluted in the vial.
- Typically, healthcare providers would then have to extract individual doses of the vaccine (0.3 mL for the Pfizer-BioNTech COVID-19 Vaccine) using syringes. One vial of Pfizer-BioNTech COVID-19 vaccine contains six doses of vaccine after dilution[1].
- AVID automates this step of extraction of the vaccine from the vial into six individual syringes, including the dispersing of bubbles inside the syringes.
- AVID also automatically uncaps and recaps the syringes during the transfer of vaccine from vials to syringes.
- It is easy to use at just the push of some buttons, only needing simple training without any special qualifications required.

Benefits:

- Reduces workload of healthcare providers, by freeing them from the manual step of extracting vaccines from vials to syringes.
- Allows more focused attention by healthcare providers on interacting and communicating with people receiving the vaccinations.
- Increases productivity at vaccination centres via introduction of automated processes that are accurate, consistent, and fast.
- Reduces risks of cross-contamination and vaccine wastage via safe handling by the machine.
- Improves safety for healthcare providers by reducing the handling of sharp syringes during the extraction step.
- The machine's small footprint and low weight (less than 25kg) means it can be easily deployed to any vaccination centre.

Development and Deployment:

- AVID was developed within six weeks from conceptualisation. It is the result of a collaboration between A*STAR's ARTC and SIMTech, which provided expertise in robotics, automation and Industry 4.0 technologies, and Sysmatic Global which designed, integrated and constructed the machine.
- AVID has been deployed to at least seven vaccination centres so far, which administer the Pfizer-BioNTech COVID-19 Vaccine. Thomson Medical, a vaccination centre operator, also supported A*STAR in the development and trials of the machine.

[1] Health Sciences Authority, Singapore - Fact sheet for healthcare providers administering Pfizer-BioNTech COVID-19 vaccine https://bit.ly/3ikKZYt

For media queries and clarifications, please contact:
Mr Robin Chan
Head, Corporate Communications
Agency for Science, Technology and Research
Tel: +65 6826 6281
Mobile: +65 9830 2610
Email: robin_chan@hq.a-star.edu.sg

Mr Khoo Kiak Nee
Director, Sysmatic Global
Tel : +65 6246 6859
Mobile : +65 9688 2502
Email : knkhoo@sysmaticgpl.com

About the Agency for Science, Technology and Research (A*STAR)

The Agency for Science, Technology and Research (A*STAR) is Singapore's lead public sector R&D agency. Through open innovation, we collaborate with our partners in both the public and private sectors to benefit the economy and society. As a Science and Technology Organisation, A*STAR bridges the gap between academia and industry. Our research creates economic growth and jobs for Singapore, and enhances lives by improving societal outcomes in healthcare, urban living, and sustainability. A*STAR plays a key role in nurturing scientific talent and leaders for the wider research community and industry. A*STAR's R&D activities span biomedical sciences to physical sciences and engineering, with research entities primarily located in Biopolis and Fusionopolis. For ongoing news, visit www.a-star.edu.sg.

Follow us on
- Facebook: https://www.facebook.com/ASTARSG/
- LinkedIn: https://www.linkedin.com/company/astarsg/
- Instagram: https://www.instagram.com/astarsg/
- YouTube: https://www.youtube.com/astartv
- Twitter: https://twitter.com/astarsg

About Sysmatic Global

Sysmatic Global Pte Ltd was established in 2010, as an appointed agent & solution provider for Nitto Seiko, Japan, assembly products. Through the years, we had developed our own design team and evolved to a system integrator providing innovative automation solution improving customer factory productivity and quality. Coupled with In-house Precision Machining & Sheetmetal fabrication facilities, we strike to provide a full turnkey solution to our customers.

Copyright 2021 ACN Newswire. All rights reserved. www.acnnewswire.com

source https://www.acnnewswire.com/press-release/english/69971/

Motul Celebrates Golden Jubilee of the Iconic 300V

Singapore, Sep 30, 2021 - (JCN Newswire) - Singapore, Sept 30, 2021 - (ACN Newswire) - Motul emerged as a pioneer of the lubricant industry in 1971 with the launch of the world's first fully synthetic ester-based lubricant, the 300V. This new grade of lubricant ushered a shift in the paradigm of what could be achieved with cutting-edge technology in motor oils. Motul had not only created a revolutionary product, but also achieved unprecedented performance and reliability on the race track. 2021 is a significant milestone for Motul, marking the completion of half a century of the 300V brand. This year, Motul celebrates the illustrious journey of their flagship product. This celebration would not be completed without Motul's discerning customers who have contributed to Motul's success on and off the track. Share the love for Motul by using #LegendaryPowerRefined to join in on the celebration.

Since 1853, Motul has been producing the highest quality of engine lubricants. The 300V is the embodiment of Motul's values and vision to provide a catalyst for high performance engines and evolve alongside those technologies year on year. Inspired by Motul's 300 victories, the brand 300V was launched as a new fully synthetic motor oil. Although available commercially today, the 300V was initially synthesized solely for racing applications. It was engineered with synthetic base oils and ester additives to create perfect synergy of power and reliability. The technological breakthrough, called ESTERCore®, allowed the 300V to maintain its competencies under extreme conditions and constant stress, immediately gaining a reputation as the perfect oil for winning.

300V Timeline

There is a 300V lubricant for every type of engine and application to best suit the engine and keep it performing at the highest level. Motul has made sure to bring the latest racing technology to everyday consumers, perpetually improving their formula from feedback and cooperation from international competitions. Beyond the 300V, Motul provides a range of products including the 8100, H-Tech, RBF, ATF, CVTF and DCTF for other parts of the car.

In the coming months, Motul Asia Pacific will collaborate with some of the region's top experts to test Motul lubricants first-hand and give feedback. Motul fans will be able to check out the experts' reviews via their Social Media channels (watch out for #LegendaryPowerRefined) and on Motul channels.

50 years of the 300V marks an unprecedented achievement for the company. The legacy of this iconic lubricant is built upon a foundation of technological advancements and Motul remains committed to staying at the forefront of the development curve for decades to come.

About Motul

Motul is a world-class French company specialised in the formulation, production and distribution of high-tech engine lubricants (two-wheelers, cars and other vehicles) as well as lubricants for industry via its Motul Tech activity. Motul offers a whole range of products for everyday car use, including the 8100, H-tech, RBF series, ATF, CVTF and DCTF among others. Motul products ensure all parts of the car are kept in pristine condition to extract maximum performance and reliability.

Unanimously recognised for more than 150 years for the quality of its products, innovation capacity and involvement in the field of competition, Motul is also recognised as a specialist in synthetic lubricants. As early as 1971, Motul was the first lubricant manufacturer to pioneer the formulation of a 100% synthetic lubricant, issued from the aeronautical industry, making use of esters technology: 300V lubricant. 2021 marks the 50th anniversary of the Motul 300V.

Motul is a partner to many manufacturers and racing teams in order to further their technological development in motorsports. It has invested in many international competitions as an official supplier for teams in: Road racing, Trials, Enduro, Endurance, Superbike, Supercross, Rallycross, World GT1, 24 Hours of Le Mans (cars and motorcycles), 24 Hours of Spa, Le Mans Series, Andros Trophy, Paris-Dakar, 8 Hours of Suzuka, Bol d'Or, Daytona 200-mile motorcycle race.

MOTUL Asia Pacific Pte. Ltd
1A International Business Park, #06-03
Singapore 609933
www.motul.com

For more information, please contact Motul at pr@motul.com.sg



Copyright 2021 JCN Newswire. All rights reserved. www.jcnnewswire.com Via JCN Newswire https://ift.tt/3tXPATt

昭和電工、2021年10月1日付人事異動を発表

TOKYO, Sep 30, 2021 - (JCN Newswire) - 昭和電工は本日、2021年10月1日付人事異動を下記の通り発表しました。

発令日:2021年10月1日
[部門長の異動]

新職: 産業ガス事業部 産業ガス統括部長
旧職: 産業ガス事業部
継続職: -
氏名: 原田 守

新職: カーボン事業部 アジアビジネス統括部長
旧職: カーボン事業部 グローバル統括部長
継続職: -
氏名: 島圖(シマズ) 良和

新職: カーボン事業部 グローバル統括部長
旧職: 戦略企画部
継続職: -
氏名: 田中 卓

本リリースの詳細は下記URLをご参照ください。
https://www.sdk.co.jp/news.html

概要:昭和電工株式会社

詳細は www.sdk.co.jp をご覧ください。


Copyright 2021 JCN Newswire. All rights reserved. www.jcnnewswire.com Via JCN Newswire https://ift.tt/3tXPATt

CITIC Telecom CPC Partners With Zscaler To Launch Cloud-Native TrueCONNECT(TM) SASE Service To Secure Expanding SD-WAN Edge

HONG KONG, Sep 30, 2021 - (JCN Newswire) - CITIC Telecom International CPC Limited ("CITIC Telecom CPC"), a wholly-owned subsidiary of CITIC Telecom International Holdings Limited (SEHK: 1883), is partnering with Zscaler, the leader in cloud security, to launch TrueCONNECT(TM) SASE Service. The new cloud-native Secure Access Service Edge (SASE) integrates with the Zscaler Zero Trust Exchange(TM) Platform to keep expanding network edges secure.

The announcement follows increasing interest in SASE deployments as network edge attacks increase. According to Gartner, at least 60% of enterprises will have explicit strategies and timelines for SASE adoption encompassing user, branch, and edge access by 2025, up from 10% in 2020 . The integration of TrueCONNECT(TM) SASE Service with the Zscaler Zero Trust Exchange(TM) offers users holistic protection for the entire SD-WAN network topologies.

"The rise in SD-WAN deployment sees an escalation of network edge attacks. Our partnership with leading zero trust and web security solution provider Zscaler to offer TrueCONNECT(TM) SASE Service expands our existing TrueCONNECT(TM) Hybrid SD-WAN value proposition," said Taylor Lam, Chief Strategy Officer of CITIC Telecom CPC. "The main benefactors of this partnership will be our customers who can now protect their network edges and scale the security as their network edges evolve."

Companies are increasingly adopting SD-WAN to support hybrid workforces and distributed workloads. They also need an agile, robust, and holistic security solution that scales with their expanding network edge. Traditional on-premises network security solutions struggle to cope with the cybersecurity demands of today's distributed enterprises, especially at the network edge. Dynamic usage patterns and a complex network landscape that includes cloud platforms and mobile technologies increase staff overheads, delay troubleshooting, and reduce scalability.

SASE takes a refreshing approach toward protecting distributed network infrastructures by relocating security at the network perimeter. It uses a granular, identity-based access model to eliminate bottlenecks and complexity while enhancing flexibility, trust, and scalability.

CITIC Telecom CPC TrueCONNECT(TM) SASE solution is a cloud-native SASE service that integrates with the Zscaler Zero Trust Exchange(TM). The powerful combination offers a Zero Trust answer for distributed enterprises looking to secure their evolving network edges while simplifying edge security management and operational costs. The solution also builds on CITIC Telecom CPC's TrueCONNECT(TM) Hybrid, a fully-managed SD-WAN connectivity solution covering nearly 60 gateways across 50 cities in 20 countries. Distributed enterprises can use the SD-WAN orchestrator to directly steer network traffic via the 150 global data centers backed by the Zscaler Zero Trust Exchange.

"Today's cyberthreats are becoming more sophisticated and frequent. Enterprises in the region need to look at holistic protection that scales as their network topology and edge grow," said Arun Dharmalingam VP, Channels and Alliances, EMEA & APJ at Zscaler. "We are delighted to partner with CITIC Telecom CPC on their innovative cloud-native SASE service built on Zscaler's zero trust architecture, and believe it will provide an important tool to keep their evolving SD-WAN network protected."

The new cloud-native TrueCONNECT(TM) SASE solution, built on Zscaler's Zero Trust Exchange(TM) offers a wide range of benefits, including:

-- Globally Distributed Comprehensive Security: TrueCONNECT(TM) SASE offers a direct-to-cloud security stack to protect digital assets, users, and devices while reinforcing business continuity, ensuring robust and responsive cybersecurity at all points of access.

-- Immediately Responsive Full Spectrum Security: Threats detected anywhere are immediately neutralized across the network for all users. TrueCONNECT(TM) SASE covers a full range of protective measures, including Browser Isolation, Cloud Access Security Broker (CASB), Cloud Security Posture Management (CSPM), Cloud Firewall/IPS, Data Loss Protection (DLP), Sandboxing, and URL Filtering.

-- Full SSL and Content Inspection: TrueCONNECT(TM) SASE gives total content visibility via full SSL inspection across all ports and protocols, with only microseconds of delay. It allows CISOs and SOC teams to monitor security activities across the SD-WAN topology easily and proactively take actions when malicious activities are detected or network usage patterns highlight an imminent attack.

--Effortless Scalability and Seamless Integration: TrueCONNECT(TM) SASE easily scales integrated policies and contextual threat visibility to accommodate additional users, security, and other business needs.

--Zero trust network access (ZTNA) capability: The service offers identity-based authentication and granular access control to empower enterprises with secure private access to cloud-native platforms or applications.

For more information about TrueCONNECT(TM) SASE, please visit: https://www.citictel-cpc.com/EN/HK/Pages/product-services/trueconnect-sase .

About CITIC Telecom CPC
We are CITIC Telecom International CPC Limited ("CITIC Telecom CPC"), a wholly owned subsidiary of CITIC Telecom International Holdings Limited (SEHK: 1883), serving multinational enterprises the world over by addressing their specific ICT requirements with highly scalable tailored solutions built upon our flagship technology suites, comprising TrueCONNECT(TM) private network solutions, TrustCSI(TM) information security solutions, DataHOUSE(TM) cloud data center solutions, and SmartCLOUD(TM) cloud computing solutions.

With the motto "Innovation Never Stops," we leverage innovative technologies, embracing AI, AR, Big Data, IoT, and other cutting-edge emerging technologies to transform technical potential into business value for our customers. As an enterprise digital transformation partner, we strive to help our customers achieving industry-leading positions, high agility, and cost-efficiency through digitalization.

With our Global-Local capabilities, we are committed to providing our customers with one-stop-shop ICT solutions with superior quality. Having a worldwide footprint across 160 countries, including Asia, Europe and America, Africa, the Middle East, and Central Asia, our global network resources connect over 160 points of presence (POPs), 18 Cloud service centers, 30+ data centers, and two dedicated 24x7 Security Operations Centers (SOCs). As one of the first managed service providers in Hong Kong to achieve multiple ICT-related certifications, including ISO 9001, 14001, 20000, 27001, and 27017, we offer local professional services, superior delivery capabilities as well as exceptional customer experience and best practices through our global presence and extensive industry know-how, becoming a leading integrated intelligent ICT service provider to enterprise customers.

For more information, please visit www.citictel-cpc.com

Media Contacts:
Micty Wong
CITIC Telecom International CPC Limited
(852) 2170 7511
Email: micty.wong@citictel-cpc.com



Copyright 2021 JCN Newswire. All rights reserved. www.jcnnewswire.com Via JCN Newswire https://ift.tt/3tXPATt

Motul Celebrates Golden Jubilee of the Iconic 300V

Singapore, Sept 30, 2021 - (ACN Newswire) - Motul emerged as a pioneer of the lubricant industry in 1971 with the launch of the world's first fully synthetic ester-based lubricant, the 300V. This new grade of lubricant ushered a shift in the paradigm of what could be achieved with cutting-edge technology in motor oils. Motul had not only created a revolutionary product, but also achieved unprecedented performance and reliability on the race track. 2021 is a significant milestone for Motul, marking the completion of half a century of the 300V brand. This year, Motul celebrates the illustrious journey of their flagship product. This celebration would not be completed without Motul's discerning customers who have contributed to Motul's success on and off the track. Share the love for Motul by using #LegendaryPowerRefined to join in on the celebration.



Since 1853, Motul has been producing the highest quality of engine lubricants. The 300V is the embodiment of Motul's values and vision to provide a catalyst for high performance engines and evolve alongside those technologies year on year. Inspired by Motul's 300 victories, the brand 300V was launched as a new fully synthetic motor oil. Although available commercially today, the 300V was initially synthesized solely for racing applications. It was engineered with synthetic base oils and ester additives to create perfect synergy of power and reliability. The technological breakthrough, called ESTERCore®, allowed the 300V to maintain its competencies under extreme conditions and constant stress, immediately gaining a reputation as the perfect oil for winning.
300V Timeline



There is a 300V lubricant for every type of engine and application to best suit the engine and keep it performing at the highest level. Motul has made sure to bring the latest racing technology to everyday consumers, perpetually improving their formula from feedback and cooperation from international competitions. Beyond the 300V, Motul provides a range of products including the 8100, H-Tech, RBF, ATF, CVTF and DCTF for other parts of the car.

In the coming months, Motul Asia Pacific will collaborate with some of the region's top experts to test Motul lubricants first-hand and give feedback. Motul fans will be able to check out the experts' reviews via their Social Media channels (watch out for #LegendaryPowerRefined) and on Motul channels.

50 years of the 300V marks an unprecedented achievement for the company. The legacy of this iconic lubricant is built upon a foundation of technological advancements and Motul remains committed to staying at the forefront of the development curve for decades to come.



About Motul

Motul is a world-class French company specialised in the formulation, production and distribution of high-tech engine lubricants (two-wheelers, cars and other vehicles) as well as lubricants for industry via its Motul Tech activity. Motul offers a whole range of products for everyday car use, including the 8100, H-tech, RBF series, ATF, CVTF and DCTF among others. Motul products ensure all parts of the car are kept in pristine condition to extract maximum performance and reliability.

Unanimously recognised for more than 150 years for the quality of its products, innovation capacity and involvement in the field of competition, Motul is also recognised as a specialist in synthetic lubricants. As early as 1971, Motul was the first lubricant manufacturer to pioneer the formulation of a 100% synthetic lubricant, issued from the aeronautical industry, making use of esters technology: 300V lubricant. 2021 marks the 50th anniversary of the Motul 300V.

Motul is a partner to many manufacturers and racing teams in order to further their technological development in motorsports. It has invested in many international competitions as an official supplier for teams in: Road racing, Trials, Enduro, Endurance, Superbike, Supercross, Rallycross, World GT1, 24 Hours of Le Mans (cars and motorcycles), 24 Hours of Spa, Le Mans Series, Andros Trophy, Paris-Dakar, 8 Hours of Suzuka, Bol d'Or, Daytona 200-mile motorcycle race.

MOTUL Asia Pacific Pte. Ltd
1A International Business Park, #06-03
Singapore 609933
www.motul.com

For more information, please contact Motul at pr@motul.com.sg


Copyright 2021 ACN Newswire. All rights reserved. www.acnnewswire.com

source https://www.acnnewswire.com/press-release/english/69943/

Global New Material, leading the new materials industry, answers in its interim report after 19-day price rally

HONG KONG, Sep 30, 2021 - (JCN Newswire) - On July 20, 2021, Global New Material International Holdings Limited ("Global New Material") (6616.HK), having developed pearlescent materials and synthetic mica as new materials in the consumer sector, ushered in strong momentum with its stock price soaring to an intraday increase of 14.68% on the third trading day following its entry into the capital market.

On July 21, August 3, August 4 and August 11, Global New Material's stock price recorded an intraday increase of 11.47%, 8.75%, 25.87 and 9.66% respectively. Over 19 trading days ended August 13, Global New Material saw its stock price rising by 104.89% and its market value exceeding HKD8 billion.

The earnings report released by the Company on August 30 shows that in the first half 2021, Global New Material recorded total revenue of RMB307 million, representing an increase of 25.3% as compared with that in the first half of 2020, a gross margin of 52.7% from 48.6% in the first half of 2020, a total gross profit of RMB162 million, representing an increase of 36.0% as compared with that in the first half of 2020, and a total profit attributable to the parent company of RMB94.10 million, representing a significant increase of 54.3%.

For now it appears that the capital market values the growth potential of Global New Material in the field of pearlescent materials. In the future, with the continued endogenous growth of the industry and the Company's industry-leading role, Global New Material's stock price momentum at the moment could be only the beginning.

Strong growth in multiple businesses drove revenue

Global New Material is specialized in pearlescent pigment products, coatings, mica and other related products. When measuring revenue in 2020, Global New Material is the world's largest producer of synthetic mica-based pearlescent pigments, the world's fourth-largest producer of pearlescent pigments, and the producer of pearlescent pigments with the highest market share in China.

In the first half of 2021, natural mica-based pearlescent pigment products, synthetic mica-based pearlescent pigment products and glass flake-based pearlescent pigment products, which accounted for the largest part of Global New Material's total revenue, had their revenues increasing by 20.7%, 31.2% and 46.3% respectively and contributed to 25.3%, equivalent to RMB307 million, in the increase in Global New Material's total revenue.

Impressive increase in gross margin and expense ratio further drove up net profit rate

Synthetic mica-based, glass flake-based and silica-based products are more profitable than natural mica-based products. In the first half of 2021, the revenue of these three types of products accounted for 44.4% of Global New Material's total revenue, representing an increase from 41.9% in the first half of 2020, which led to a remarkable rise in Global New Material's gross margin to 52.7% from 48.6% in the first half of 2020.

With the growth in both revenue and gross margin, Global New Material had its final net profit increasing significantly by 56.5% to RMB98.181 million, and its net margin increasing by 6.4 percentage points to 32%.

Great market potential and capacity expansion support future growth

Pearlescent pigments are advantageous over traditional pigments in terms of fading resistance, nontoxicity, safety and environmental friendliness, and therefore are rapidly replacing traditional pigments.

Compared with natural mica-based pigments, synthetic mica-based pearlescent pigments perform much better in terms of glossiness, transparency and high-temperature resistance, and generally do not contain heavy metals. Therefore, synthetic mica-based pearlescent pigments are more suitable for the fast-growing high-end markets such as automobiles and cosmetics.

According to a Frost-Sullivan report, the global market size of synthetic mica products is expected to exceed that of natural mica products in 2022; the market size of synthetic mica products and natural mica products will reach RMB15.4 billion and RMB9.7 billion respectively by 2025; the market size of synthetic mica-based products in China is expected to expand by 39.7% in the next five years and reach RMB7.6 billion by 2025.

In 2020, Global New Material came close to full capacity, with pearlescent pigments and synthetic mica products reaching nearly 14,000 tons and 10,000 tons respectively. Global New Material's phase-2 plants are under construction, and once put into production, are expected to realize a capacity of 30,000 tons of pearlescent pigments and 30,000 tons of synthetic mica products. Forecast by Global New Material, a capacity of 6,000 tons of pearlescent pigments will be realized in the fourth quarter of this year, and a capacity of 6,000 tons of synthetic mica products will be realized in the second quarter of next year, which will lead to a further growth of Global New Material's performance.

Media contact:
Haolu Wang, Peanutmedia
E: wanghaolu@czgmcn.com
T: +86 18345 162685
W: www.Peanutmedia.com


Copyright 2021 JCN Newswire. All rights reserved. www.jcnnewswire.com Via JCN Newswire https://ift.tt/3tXPATt

Mitrade Wins Best Forex Fintech Broker Asia 2021 Award

MELBOURNE, Sep 30, 2021 - (JCN Newswire) - Mitrade Holding Ltd, a financial technology company offering Forex and OTC derivatives online trading, has been crowned Best Forex Fintech Broker Asia for 2021.

This award is under the Global Forex Awards and is presented by Holiston Media, a leading provider of global financial awards and events. The Global Forex Awards recognizes the best performing forex brands or businesses on a global and regional level. They reward providers of groundbreaking technology, extensive market research tools, low-cost trading, world-class customer support for direct-to-consumer businesses, and more. This is a benchmark of success as award winners are nominated independently through public voting processes by real customers worldwide and others in the forex trading industry, ensuring impartiality.

Amidst the thousands of businesses in the forex industry, Mitrade emerged as one of the winning brands. By clinching the title of Best Forex Fintech Broker Asia for 2021, the company showed its popularity among customers with Mitrade's App and WebTrader - an exclusive self-developed trading platform, competitive platform fees and top-notch customer service.

"It is a great honour to receive this award and we are heartened to see recognition for our dedication to serving the global trading community, especially in Asia. We extend our deepest gratitude to our users who voted for us and supported our product and services. Our team is highly motivated to continue improving our services and we are striving towards bringing traders worldwide a better trading experience", said a representative of Mitrade Holding Ltd.

Since the company launched their proprietary trading platform back in 2019, Mitrade has witnessed robust growth and has over 800,000 users globally to date and continues to expand rapidly with offices around the globe.

Currently, there are over 100 financial instruments including Forex, Commodities, and Indices on Mitrade. A strong team of finance veterans and technology experts are behind the platform, providing unrivalled trading conditions to its customers by having an in-depth understanding of investors' needs and the expertise to improve current market offerings by creating new solutions.

On top of this Best Forex Fintech Broker Asia Award 2021, Mitrade has won the Best Mobile Application 2021 Award by World Forex Award, and the Fastest Growing Broker Australia Award from International Business Magazine for two consecutive years - 2019 and 2020. The company has a multitude of other awards, showing its consistent excellence as an online broker globally. Website: https://www.mitrade.com/about-us/awards

OTC derivatives are a leveraged product and can result in the loss of your entire capital. Website: https://www.mitrade.com/

For media inquiry, please contact Ms Belle Toh at belle.toh@mitrade.com.

About Mitrade

Mitrade Holding Ltd, the innovative financial technology company that offers OTC derivatives online trading, operates its business under the regulation of the Cayman Islands Monetary Authority (CIMA) (SIB 1612446). With a mission to make trading simplified, Mitrade provides a self-developed trading platform and over 100 markets with assets include forex, commodities, and indices that best suit investors' needs from all over the world.


Copyright 2021 JCN Newswire. All rights reserved. www.jcnnewswire.com Via JCN Newswire https://ift.tt/3tXPATt

Don Agro International and Smart Polymorph Technologies pioneer latest pharmaceutical innovations for the agricultural sector

SINGAPORE, Sep 30, 2021 - (JCN Newswire) - Don Agro International Limited (the "Company" or "Don Agro") and its subsidiaries (collectively the "Group"), one of the largest agricultural companies based in the Rostov region of Russia, is pleased to announce the launch of its joint pilot project with Smart Polymorph Technologies ("Smart Polymorph") to introduce the latest pharmaceutical innovations to optimise crop production for the agricultural sector. Headquartered in the high-tech Skolkovo Innovation Center in Moscow, Russia, Smart Polymorph specialises in developing new, improved and patentable forms of pharmaceutical substances.

As part of this pilot program, both Don Agro and Smart Polymorph are working towards enhancing crop production yields and minimising costs through the use of well-known plant growth bio-stimulants that have been modified into new crystalline and amorphous forms via the latter's polymorphic modification technology. To support research efforts, the Group earmarked experimental plots totalling 50 hectares of three different crops, namely winter wheat, corn and sunflower, as a testbed for the application of the new growth bio-stimulator.

According to Smart Polymorph, pharmaceutical drugs which they had developed prior to the latest venture displayed higher therapeutic effect as compared to existing market alternatives, even as the number of active substances used was reduced by three to five times. This is due to the technology's ability to modify the morphology and crystalline form of the respective substances, and manage the control of particle sizes and amount of impurities, thereby ensuring that the end product achieves the highest quality standards.

"Smart Polymorph harnesses a unique technology in polymorphic modification of organic substances that is suitable and can be applied to a wide variety of medicines and bioactive substances used in the agroindustrial complex," explains Mr Yakovlev Ruslan, Director of Science of Smart Polymorph Technologies. He added, "Leveraging on our proprietary technology, we have been able to modify substances that have proved to be more superior and efficient than other alternatives currently existing in the market. Backed by our successful track record to date, we are confident that the same technology can be applied to the agricultural sector to enhance the effectiveness of plant growth stimulants, pesticides and other related substances."

On this latest initiative, Mr Marat Devlet-Kildeyev, Chief Executive Officer of Don Agro commented, "Over the years, we have continued to introduce modern farming techniques, adopt new technologies and implement industry best practices to set ourselves apart from our industry peers. This has included entering the market for organic wheat as well as adopting AI-powered autonomous driving technology to enhance our crop harvesting capabilities. Our latest joint pilot program is a step in the same direction as we apply new and innovative pharmaceutical technologies to our crop fields to achieve maximum crop yields at the lowest cost. Supported by our renowned partner in Smart Polymorph Technologies, we are confident that this initiative will reinforce our position as one of the leading innovators in the agricultural sector."

Since April 2021, the Group has begun cultivating winter wheat using bio-stimulants supplied by Smart Polymorph, with experimental efforts for corn and sunflower crops next in the pipeline. Once the respective crops have been harvested, an analysis of yields and quality of the final product will be carried out by the Group to determine the growth bio-stimulant's effectiveness. The introduction of bio-stimulants does not incur additional costs to the Group as the processes and technology required for sowing seeds and growing crops remain unchanged.

About Don Agro International Limited

Don Agro is one of the largest agricultural companies in the Rostov region in Russia principally engaged in the cultivation of agricultural crops and production of raw milk. The Group is also engaged in crop production in the Volgograd region in Russia. The Group has a total controlled land bank of 67,340 hectares, of which more than 54,420 hectares are arable land. The Group owns approximately 17,200 hectares of its controlled land bank.

The Group's operations are principally located in the Rostov region, one of the most fertile regions of Russia, situated close to the Azov and Black Seas and the Don River which house major international ports. The Group's second operating division in the Volgograd region is located in close proximity to key trading routes including the Volga River. This allows the Group's customers, who are mainly traders and exporters, to save on transportation costs and, as a result, be able to offer higher prices for the Group's crops. Within the crop production segment, the Group is primarily engaged in the farming of commercial crops such as winter wheat, sunflower and corn.

In addition, the Group is the largest milk producer in the Rostov region and owns more than 4,000 heads of dairy cattle which includes approximately 2,200 milking cows.

Equity information at SGX:GRQ, Bloomberg DAG:SP, Reuters DONA:SI.

Issued for and on behalf Don Agro by Financial PR.

For more information please contact:
Jonathan Wee
tech@financialpr.com.sg
Tel: +65 6438 2990, Fax: +65 6438 0064

Don Agro International Limited (the "Company") was listed on Catalist of the Singapore Exchange Securities Trading Limited (the "Exchange") on 14 February 2020. The initial public offering of the Company was sponsored by PrimePartners Corporate Finance Pte. Ltd. (the "Sponsor").

This press release has been reviewed by the Company's Sponsor. It has not been examined or approved by the Exchange and the Exchange assumes no responsibility for the contents of this document, including the correctness of any of the statements or opinions made or reports contained in this document.

The contact person for the Sponsor is Mr Joseph Au, 16 Collyer Quay, #10-00 Income at Raffles, Singapore 049318, sponsorship@ppcf.com.sg


Copyright 2021 JCN Newswire. All rights reserved. www.jcnnewswire.com Via JCN Newswire https://ift.tt/3tXPATt

CITIC Telecom CPC Partners With Zscaler To Launch Cloud-Native TrueCONNECT(TM) SASE Service To Secure Expanding SD-WAN Edge

HONG KONG, Sep 30, 2021 - (ACN Newswire) - CITIC Telecom International CPC Limited ("CITIC Telecom CPC"), a wholly-owned subsidiary of CITIC Telecom International Holdings Limited (SEHK: 1883), is partnering with Zscaler, the leader in cloud security, to launch TrueCONNECT(TM) SASE Service. The new cloud-native Secure Access Service Edge (SASE) integrates with the Zscaler Zero Trust Exchange(TM) Platform to keep expanding network edges secure.

The announcement follows increasing interest in SASE deployments as network edge attacks increase. According to Gartner, at least 60% of enterprises will have explicit strategies and timelines for SASE adoption encompassing user, branch, and edge access by 2025, up from 10% in 2020 . The integration of TrueCONNECT(TM) SASE Service with the Zscaler Zero Trust Exchange(TM) offers users holistic protection for the entire SD-WAN network topologies.

"The rise in SD-WAN deployment sees an escalation of network edge attacks. Our partnership with leading zero trust and web security solution provider Zscaler to offer TrueCONNECT(TM) SASE Service expands our existing TrueCONNECT(TM) Hybrid SD-WAN value proposition," said Taylor Lam, Chief Strategy Officer of CITIC Telecom CPC. "The main benefactors of this partnership will be our customers who can now protect their network edges and scale the security as their network edges evolve."

Companies are increasingly adopting SD-WAN to support hybrid workforces and distributed workloads. They also need an agile, robust, and holistic security solution that scales with their expanding network edge. Traditional on-premises network security solutions struggle to cope with the cybersecurity demands of today's distributed enterprises, especially at the network edge. Dynamic usage patterns and a complex network landscape that includes cloud platforms and mobile technologies increase staff overheads, delay troubleshooting, and reduce scalability.

SASE takes a refreshing approach toward protecting distributed network infrastructures by relocating security at the network perimeter. It uses a granular, identity-based access model to eliminate bottlenecks and complexity while enhancing flexibility, trust, and scalability.

CITIC Telecom CPC TrueCONNECT(TM) SASE solution is a cloud-native SASE service that integrates with the Zscaler Zero Trust Exchange(TM). The powerful combination offers a Zero Trust answer for distributed enterprises looking to secure their evolving network edges while simplifying edge security management and operational costs. The solution also builds on CITIC Telecom CPC's TrueCONNECT(TM) Hybrid, a fully-managed SD-WAN connectivity solution covering nearly 60 gateways across 50 cities in 20 countries. Distributed enterprises can use the SD-WAN orchestrator to directly steer network traffic via the 150 global data centers backed by the Zscaler Zero Trust Exchange.

"Today's cyberthreats are becoming more sophisticated and frequent. Enterprises in the region need to look at holistic protection that scales as their network topology and edge grow," said Arun Dharmalingam VP, Channels and Alliances, EMEA & APJ at Zscaler. "We are delighted to partner with CITIC Telecom CPC on their innovative cloud-native SASE service built on Zscaler's zero trust architecture, and believe it will provide an important tool to keep their evolving SD-WAN network protected."

The new cloud-native TrueCONNECT(TM) SASE solution, built on Zscaler's Zero Trust Exchange(TM) offers a wide range of benefits, including:

-- Globally Distributed Comprehensive Security: TrueCONNECT(TM) SASE offers a direct-to-cloud security stack to protect digital assets, users, and devices while reinforcing business continuity, ensuring robust and responsive cybersecurity at all points of access.

-- Immediately Responsive Full Spectrum Security: Threats detected anywhere are immediately neutralized across the network for all users. TrueCONNECT(TM) SASE covers a full range of protective measures, including Browser Isolation, Cloud Access Security Broker (CASB), Cloud Security Posture Management (CSPM), Cloud Firewall/IPS, Data Loss Protection (DLP), Sandboxing, and URL Filtering.

-- Full SSL and Content Inspection: TrueCONNECT(TM) SASE gives total content visibility via full SSL inspection across all ports and protocols, with only microseconds of delay. It allows CISOs and SOC teams to monitor security activities across the SD-WAN topology easily and proactively take actions when malicious activities are detected or network usage patterns highlight an imminent attack.

--Effortless Scalability and Seamless Integration: TrueCONNECT(TM) SASE easily scales integrated policies and contextual threat visibility to accommodate additional users, security, and other business needs.

--Zero trust network access (ZTNA) capability: The service offers identity-based authentication and granular access control to empower enterprises with secure private access to cloud-native platforms or applications.

For more information about TrueCONNECT(TM) SASE, please visit: https://www.citictel-cpc.com/EN/HK/Pages/product-services/trueconnect-sase .

About CITIC Telecom CPC
We are CITIC Telecom International CPC Limited ("CITIC Telecom CPC"), a wholly owned subsidiary of CITIC Telecom International Holdings Limited (SEHK: 1883), serving multinational enterprises the world over by addressing their specific ICT requirements with highly scalable tailored solutions built upon our flagship technology suites, comprising TrueCONNECT(TM) private network solutions, TrustCSI(TM) information security solutions, DataHOUSE(TM) cloud data center solutions, and SmartCLOUD(TM) cloud computing solutions.

With the motto "Innovation Never Stops," we leverage innovative technologies, embracing AI, AR, Big Data, IoT, and other cutting-edge emerging technologies to transform technical potential into business value for our customers. As an enterprise digital transformation partner, we strive to help our customers achieving industry-leading positions, high agility, and cost-efficiency through digitalization.

With our Global-Local capabilities, we are committed to providing our customers with one-stop-shop ICT solutions with superior quality. Having a worldwide footprint across 160 countries, including Asia, Europe and America, Africa, the Middle East, and Central Asia, our global network resources connect over 160 points of presence (POPs), 18 Cloud service centers, 30+ data centers, and two dedicated 24x7 Security Operations Centers (SOCs). As one of the first managed service providers in Hong Kong to achieve multiple ICT-related certifications, including ISO 9001, 14001, 20000, 27001, and 27017, we offer local professional services, superior delivery capabilities as well as exceptional customer experience and best practices through our global presence and extensive industry know-how, becoming a leading integrated intelligent ICT service provider to enterprise customers.

For more information, please visit www.citictel-cpc.com

Media Contacts:
Micty Wong
CITIC Telecom International CPC Limited
(852) 2170 7511
Email: micty.wong@citictel-cpc.com



Copyright 2021 ACN Newswire. All rights reserved. www.acnnewswire.com

source https://www.acnnewswire.com/press-release/english/69959/

InvestHK: HKSAR Government's "Report on Hong Kong's Business Environment" highlights Hong Kong's unique advantages and unlimited opportunities

HONG KONG, Sep 30, 2021 - (JCN Newswire) - Invest Hong Kong (InvestHK) announced today (September 29) a series of promotions building upon the "Report on Hong Kong's Business Environment: A Place with Unique Advantages and Unlimited Opportunities" (www.hkeconomy.gov.hk/en/environment/index.htm) published this week by the Government of the Hong Kong Special Administrative Region (HKSAR).

The Director-General of Investment Promotion of the HKSAR, Mr Stephen Phillips, said that the report, announced by the Financial Secretary, Mr Paul Chan, on September 27, sets out very clearly the exciting opportunities for businesses from around the world in Hong Kong and at the same time sets the record straight about international investors' misconceptions of Hong Kong as a result of persistent biased media reports in some quarters.

"The report not only outlines clearly the robust strengths of Hong Kong as an international financial, aviation, innovation and technology, legal and cultural hub, but also highlights the many attractive opportunities the city has to offer multinationals and entrepreneurs who want a reliable, efficient business base in Asia," Mr Phillips said.

"It is very important for us to tell the real Hong Kong story to the international business community that under the Central Government's support and the 'one country, two systems' principle, Hong Kong and businesses in Hong Kong have a bright future with fantastic opportunities."

Mr Phillips added, "Our pipeline remains strong with many multinationals, small and medium-sized companies and start-ups still planning to come to our city to develop their businesses and scale into Mainland China and wider Asia. Going forward, with the continued support of the Central Government, we see very bright prospects for Hong Kong's economy."

InvestHK is organising a series of global webinars to be held on October 7 for business communities around the world to provide an update on Hong Kong's latest business environment and key announcements relevant to business in next week's Policy Address.

A short video summarising the report can be found at https://youtu.be/zhSxxEo32l4.


Copyright 2021 JCN Newswire. All rights reserved. www.jcnnewswire.com Via JCN Newswire https://ift.tt/3tXPATt

Don Agro International and Smart Polymorph Technologies pioneer latest pharmaceutical innovations for the agricultural sector

SINGAPORE, Sep 30, 2021 - (ACN Newswire) - Don Agro International Limited (the "Company" or "Don Agro") and its subsidiaries (collectively the "Group"), one of the largest agricultural companies based in the Rostov region of Russia, is pleased to announce the launch of its joint pilot project with Smart Polymorph Technologies ("Smart Polymorph") to introduce the latest pharmaceutical innovations to optimise crop production for the agricultural sector. Headquartered in the high-tech Skolkovo Innovation Center in Moscow, Russia, Smart Polymorph specialises in developing new, improved and patentable forms of pharmaceutical substances.

As part of this pilot program, both Don Agro and Smart Polymorph are working towards enhancing crop production yields and minimising costs through the use of well-known plant growth bio-stimulants that have been modified into new crystalline and amorphous forms via the latter's polymorphic modification technology. To support research efforts, the Group earmarked experimental plots totalling 50 hectares of three different crops, namely winter wheat, corn and sunflower, as a testbed for the application of the new growth bio-stimulator.

According to Smart Polymorph, pharmaceutical drugs which they had developed prior to the latest venture displayed higher therapeutic effect as compared to existing market alternatives, even as the number of active substances used was reduced by three to five times. This is due to the technology's ability to modify the morphology and crystalline form of the respective substances, and manage the control of particle sizes and amount of impurities, thereby ensuring that the end product achieves the highest quality standards.

"Smart Polymorph harnesses a unique technology in polymorphic modification of organic substances that is suitable and can be applied to a wide variety of medicines and bioactive substances used in the agroindustrial complex," explains Mr Yakovlev Ruslan, Director of Science of Smart Polymorph Technologies. He added, "Leveraging on our proprietary technology, we have been able to modify substances that have proved to be more superior and efficient than other alternatives currently existing in the market. Backed by our successful track record to date, we are confident that the same technology can be applied to the agricultural sector to enhance the effectiveness of plant growth stimulants, pesticides and other related substances."

On this latest initiative, Mr Marat Devlet-Kildeyev, Chief Executive Officer of Don Agro commented, "Over the years, we have continued to introduce modern farming techniques, adopt new technologies and implement industry best practices to set ourselves apart from our industry peers. This has included entering the market for organic wheat as well as adopting AI-powered autonomous driving technology to enhance our crop harvesting capabilities. Our latest joint pilot program is a step in the same direction as we apply new and innovative pharmaceutical technologies to our crop fields to achieve maximum crop yields at the lowest cost. Supported by our renowned partner in Smart Polymorph Technologies, we are confident that this initiative will reinforce our position as one of the leading innovators in the agricultural sector."

Since April 2021, the Group has begun cultivating winter wheat using bio-stimulants supplied by Smart Polymorph, with experimental efforts for corn and sunflower crops next in the pipeline. Once the respective crops have been harvested, an analysis of yields and quality of the final product will be carried out by the Group to determine the growth bio-stimulant's effectiveness. The introduction of bio-stimulants does not incur additional costs to the Group as the processes and technology required for sowing seeds and growing crops remain unchanged.

About Don Agro International Limited

Don Agro is one of the largest agricultural companies in the Rostov region in Russia principally engaged in the cultivation of agricultural crops and production of raw milk. The Group is also engaged in crop production in the Volgograd region in Russia. The Group has a total controlled land bank of 67,340 hectares, of which more than 54,420 hectares are arable land. The Group owns approximately 17,200 hectares of its controlled land bank.

The Group's operations are principally located in the Rostov region, one of the most fertile regions of Russia, situated close to the Azov and Black Seas and the Don River which house major international ports. The Group's second operating division in the Volgograd region is located in close proximity to key trading routes including the Volga River. This allows the Group's customers, who are mainly traders and exporters, to save on transportation costs and, as a result, be able to offer higher prices for the Group's crops. Within the crop production segment, the Group is primarily engaged in the farming of commercial crops such as winter wheat, sunflower and corn.

In addition, the Group is the largest milk producer in the Rostov region and owns more than 4,000 heads of dairy cattle which includes approximately 2,200 milking cows.

Equity information at SGX:GRQ, Bloomberg DAG:SP, Reuters DONA:SI.

Issued for and on behalf Don Agro by Financial PR.

For more information please contact:
Jonathan Wee
tech@financialpr.com.sg
Tel: +65 6438 2990, Fax: +65 6438 0064

Don Agro International Limited (the "Company") was listed on Catalist of the Singapore Exchange Securities Trading Limited (the "Exchange") on 14 February 2020. The initial public offering of the Company was sponsored by PrimePartners Corporate Finance Pte. Ltd. (the "Sponsor").

This press release has been reviewed by the Company's Sponsor. It has not been examined or approved by the Exchange and the Exchange assumes no responsibility for the contents of this document, including the correctness of any of the statements or opinions made or reports contained in this document.

The contact person for the Sponsor is Mr Joseph Au, 16 Collyer Quay, #10-00 Income at Raffles, Singapore 049318, sponsorship@ppcf.com.sg

Copyright 2021 ACN Newswire. All rights reserved. www.acnnewswire.com

source https://www.acnnewswire.com/press-release/english/69954/

ラックスリサーチ、産業部門の脱炭素化技術を評価するためのフレームワークを取り上げたレポートを発表

マサチューセッツ州ボストン - 2021年9月30日 - (JCN Newswire) - 産業部門は世界の二酸化炭素(CO2)排出量の21%を占めており、セメント、製鋼、化学工業などの産業部門が中心となり、年間9ギガトン以上のCO2を排出しています。そのため、セメント、製鋼、化学工業の3産業を脱炭素化することのみで、世界の産業排出量は半分まで削減することが可能となります。ただし、これら産業は長期的に成長し続けることが予測されており、増加する製品需要を満たしつつも、いかにカーボンニュートラリティを達成することができるか、という点が、産業部門における脱炭素化の大きな課題です。

産業部門において脱炭素化へ向けたロードマップを確立するためには、現在、そして将来的に利用可能な技術を深く理解し、今後より厳しくなることが予想される気候・環境政策や規制にも適切に対応できるよう、準備を進めていくことが不可欠です。

そこで、ラックスリサーチの新しい報告書、『Decarbonization of Industry: The Path Toward Carbon Neutrality(産業部門の脱炭素化:カーボンニュートラリティへの道のり)』は、産業部門における脱炭素化技術を評価するためのフレームワークを紹介しました。

脱炭素技術は、導入の複雑さという観点から、3つのレベルに分類することができます。

  • 当座しのぎの技術(Makeshift technologies:これら技術は産業プロセスの主要段階を変更することなく排出量の削減に貢献します。これらは、効率面におけるギャップ、原料の炭素集約度、またはプロセスの最後に放出される廃棄物への対応による脱炭素化を目指すものであり、工業プロセスのコア技術および基本は変わりません。
  • 後付け(レトロフィット)技術(Retrofit technologies:これら技術は、産業プロセスの一つまたは複数の主要段階を変更することで排出量を削減します。これらは、既存のプロセスフロー内に収まる新しい低炭素バリアントをコアプロセスユニットに追加したり入れ替えたりすることで脱炭素化を目指します。ただし工業プロセスの基本は変わりません。
  • 変革技術(Transformational technologies:これら技術は、産業プロセスの根本を変えることで排出量を削減します。これらの技術は、既存の主要なプロセスユニットを排除し、既存の産業プロセスフローを完全に変換することによって脱炭素化を目指します。これらは、主に、熱化学プラットフォームを生化学または電気化学プラットフォームに置き換えることになります。

ラックスリサーチのシニアアナリスト、Runeel Daliahは次のように説明しています。

『これらの3つのレベルの技術は、産業の脱炭素化の構成要素と考えられるべきです。産業の脱炭素化は、あたかも単一の概念であるかのように取り上げられることが多いものの、産業部門の各種課題に対応可能な唯一のアプローチや解決策というものは存在しません。産業部門の脱炭素化は、特定の産業およびそのコアプロセスに特有の、多様な技術それぞれに適用することによって実現されます。

ただし、産業部門の脱炭素化は非常に複雑であるのが現状です。産業部門の工場やプラントは、しばしば数十億ドルにも及ぶ高額の投資を必要とし、数十年をかけて建設されてきました。2050年までにカーボンニュートラリティ達成を目指す企業は、過去3世紀にわたって依存してきた熱化学プラットフォームから、わずか30年で、変革技術を活用し、脱炭素を達成する必要があります。

また、産業部門の脱炭素化は、工業製品における競争上の懸念をもたらします。コンシューマー側で低炭素製品の採用を促進する規制がなければ、脱炭素化は地域レベル、あるいは世界レベルで産業界の競争力低下につながる可能性があります。化石燃料を基盤とした製造に対する経済的ペナルティのみでは、産業部門の脱炭素化を支援するには不十分です。世界的に産業部門がカーボンニュートラリティへと移行するためには、各国において低炭素製品の輸入や消費に対するインセンティブを導入することが必要です。』

詳細はレポートのエグゼクティブサマリーをダウンロードしてご確認ください。

また本調査を担当したRuneel Daliahへのインタビューは、press@luxresearchinc.comより受け付けております。

ラックスリサーチについて

ラックスリサーチ(本社:米国ボストン)は先端技術の事業性評価・動向調査を専門とする米系調査会社です。世界の大手企業、政府系機関、コーポレートベンチャーキャピタル、大学、スタートアップ企業を主なクライアントとし、先端技術が生み出す事業機会特定をサポートしています。

データに基づく分析。信頼できるオピニオン。より良い意思決定を、より早く。

詳細は www.luxresearchinc.com/ja/homeをご覧ください。またEight企業ページLinkedInやTwitter (@LuxResearch)にてラックスリサーチの最新情報をフォローしていただくことが可能です。

お問い合わせ先:
ラックスリサーチ
戸口久子
hisako.toguchi@luxresearchinc.com




Copyright 2021 JCN Newswire. All rights reserved. www.jcnnewswire.com Via JCN Newswire https://ift.tt/3tXPATt